A Rutgers Health-led survey finds most people in HIV care would choose injections over daily pills, yet few are on the regimen.

Aedes aegypti, commonly known as the yellow fever mosquito, is a highly adapted, invasive mosquito species recognized as a major global health threat that acts as the primary vector for several severe diseases, most notably dengue fever, as well as yellow fever, chikungunya and Zika virus. Local government agencies conduct routine molecular surveillance of these mosquitoes to detect and track viruses, however, they are primarily limited to using conventional reverse transcription polymerase chain reaction methodologies, which can only detect known pathogens that have already been identified and for which specific genetic primers have been developed.

 

Recent research efforts applying high-throughput RNA sequencing have led to a large expansion in the mosquito virome (the entire collection of viruses contained within mosquitoes). However, questions remain as to how persistent insect viruses are within mosquito colonies, how insect viruses interact with mosquito immune responses and how frequently insect viruses can be transmitted.

 

A new study by Boston University Chobanian & Avedisian School of Medicine researchers looked at the mosquitoes’ immune response to discover many more insect viruses and they hope to someday use the mosquitoes’ own immune system to battle some of the most pervasive and antagonistic human viruses.

The EU project PANORAMIX, coordinated by DTU, indicates that mixtures of man-made chemicals present in human blood or breast milk may affect reproductive health and child development - even when individual substances are within accepted safety levels.

The Keck School of Medicine of USC and Keck Medicine of USC have launched collaborations with Tempus AI, Inc., a technology company at the forefront of applying AI to precision medicine, to integrate clinical care, clinical trials and research through a unified framework. The new framework intends to create an ongoing cycle of learning between patient care and research, with a primary goal of improving outcomes for the more than 1.5 million annual patient visits to Keck Medicine of USC hospitals and clinics. It is designed to promote more personalized and precise care to patients across the Keck Medicine of USC health system with tailored recommendations informed by large-scale clinical data. At the same time, it seeks to use clinical data to inform and accelerate research to develop innovative therapies and algorithms that may translate for public benefit. At the heart of the USC -Tempus collaboration is the pioneering research and patient care delivered by the USC Norris Comprehensive Cancer Center. The strategic undertaking is anchored by four key pillars. These include clinical testing, which can enable detailed molecular and genetic profiling at the patient level; clinical trials matching, which automatically matches eligible patients with novel targeted therapies; clinical care gap pathways, which uses AI-driven insights to promote evidence-based patient care; and research collaboration and co-development, aimed at moving academic discoveries into real-world diagnostics and treatments. Together, these elements have the potential to create an integrated ecosystem that connects patient care and research. This collaboration will start with a focus on precision oncology, with the intension of creating a proven model for integrating care and research, that can then be extended over time to other specialties, including cardiology, neurology and radiology.

The security of every nation faces an increasingly severe and frequent threat: disruptions to nature. In this Q&A, Bradley J. Cardinale, Penn State professor of ecosystem science and management, discussed his recent study examining how disrupted ecosystems can lead to increased risk for food security, water availability, health and well-being, as well as crime. 

Researchers at LMU have developed a human cell model that replicates key mechanisms of neurodegenerative diseases – with potential for novel therapies.